Incyte (INCY) Income from Continuing Operations (2010 - 2026)
Incyte (INCY) posted Income from Continuing Operations of 303330000.0 for Q1 2026, up 1.35% on a QoQ basis from 299279000.0 in Q4 2025, and up 91.73% year-over-year from 158203000.0 in Q1 2025.
Incyte (INCY) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Incyte's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 303330000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 91.73% year-over-year to 303330000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1431777000.0 (up 6631.44% YoY) and the FY2025 annual result came in at 1286650000.0, up 3844.96% from the prior year.
- Income from Continuing Operations was 303330000.0 for Q1 2026 at Incyte, up from 299279000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 424169000.0 in Q3 2025 and bottomed at 444601000.0 in Q2 2024.
- A 5-year average of 150638470.59 and a median of 169548000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 681.22% in 2024, while the deepest fall reached 318.43% in 2024.
- Incyte's Income from Continuing Operations stood at 28461000.0 in 2022, then soared by 606.51% to 201079000.0 in 2023, then increased by 0.07% to 201212000.0 in 2024, then jumped by 48.74% to 299279000.0 in 2025, then rose by 1.35% to 303330000.0 in 2026.
- Business Quant data shows INCY's Income from Continuing Operations at 303330000.0 in Q1 2026, 299279000.0 in Q4 2025, and 424169000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Incyte | 23.33 Bn | 19.32 Bn | 1.17 Bn | 303.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 303.33 Mn |
| Dec 31, 2025 | 299.28 Mn |
| Sep 30, 2025 | 424.17 Mn |
| Jun 30, 2025 | 405.00 Mn |
| Mar 31, 2025 | 158.20 Mn |
| Dec 31, 2024 | 201.21 Mn |
| Sep 30, 2024 | 106.46 Mn |
| Jun 30, 2024 | -444.60 Mn |
| Mar 31, 2024 | 169.55 Mn |
| Dec 31, 2023 | 201.08 Mn |
| Sep 30, 2023 | 171.27 Mn |
| Jun 30, 2023 | 203.55 Mn |
| Mar 31, 2023 | 21.70 Mn |
| Dec 31, 2022 | 28.46 Mn |
| Sep 30, 2022 | 112.78 Mn |
| Jun 30, 2022 | 161.43 Mn |
| Mar 31, 2022 | 37.99 Mn |
| Dec 31, 2021 | 563.86 Mn |
| Sep 30, 2021 | 181.74 Mn |
| Jun 30, 2021 | 149.46 Mn |